Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chenodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 7/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 1.00 |
| ▸ | ENPP2 | Q13822 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chenodiol SCHEMBL22079588 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24199134 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23517166 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22079179 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337643 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24124587 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25397934 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24061005 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23704676 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337648 | 1.00 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11313866-B2 | Method of diagnosing and treating asphyxia | INFANDX AG (DE) | 2022-04-26 | — | — | US | disclosed |
| US-11117926-B2 | Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases | BAR PHARMACEUTICALS S.R.L. (IT) | 2021-09-14 | — | — | US | disclosed |
| US-20210139528-A1 | CRYSTALLINE FORMS OF OBETICHOLIC ACID | INTERCEPT PHARMACEUTICALS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2020128514-A1 | 2-FLUORINATED BILE ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NZP UK Limited (GB) | 2020-06-25 | — | — | WO | disclosed |
| EP-2249161-B1 | Method of diagnosing asphyxia | INFANDX AG (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-20190352328-A1 | CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES | BAR PHARMACEUTICALS S.R.L. (IT) | 2019-11-21 | — | — | US | disclosed |
| US-10414791-B2 | Methods for preparation of bile acids and derivatives thereof | INTERCEPT PHARMACEUTICALS, INC (US) | 2019-09-17 | — | — | US | disclosed |
| US-10407462-B2 | Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases | BAR PHARMACEUTICALS S.R.L. (IT) | 2019-09-10 | — | — | US | disclosed |
| EP-3482797-A1 | INHIBITORS OF ALPHA-CRYSTALLIN AGGREGATION FOR THE TREATMENT FOR CATARACT | The Regents Of The University Of Michigan (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2874709-B1 | INHIBITORS OF ALPHA-CRYSTALLIN AGGREGATION FOR THE TREATMENT FOR CATARACT | UNIV MICHIGAN REGENTS (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-2427773-A1 | METHOD OF DIAGNOSING ASPHYXIA | Keller, Matthias (DE) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011000753-A1 | METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES | BIOCRATES LIFE SCIENCES AG (AT) | 2011-01-06 | — | — | WO | disclosed |
| EP-2270699-A1 | Method for normalization in metabolomics analysis methods with endogenous reference metabolites | BIOCRATES Life Sciences AG (AT) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010128054-A1 | METHOD OF DIAGNOSING ASPHYXIA | BIOCRATES LIFE SCIENCES AG (AT) | 2010-11-11 | — | — | WO | disclosed |
| US-7524836-B2 | Nitrooxyderivative steroidal compounds | NICOX S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| US-7524836-B2 | Nitrooxyderivative steroidal compounds | NICOX S.A. (FR) | 2009-04-28 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-20070142342-A1 | Pharmaceutical compounds | NICOX S.A. | 2007-06-21 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
| US-7186708-B2 | Steroidal compounds | NICOX S.A. (FR) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142342-A1 | Pharmaceutical compounds | CYP11B2, CYP11B1, CYP2S1 | NR1H4 171/4885GPBAR1 94/4885ABCB11 88/4885 |
| US-11117926-B2 | Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases | GPBAR1, NR1H4, SLC10A1 | NR1H4 2/4885GPBAR1 1/4885ABCB11 9/4885 |
| US-20190352328-A1 | CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES | GPBAR1, NR1H4, SLC10A1 | NR1H4 2/4885GPBAR1 1/4885ABCB11 9/4885 |
| US-10407462-B2 | Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases | GPBAR1, NR1H4, SLC10A1 | NR1H4 2/4885GPBAR1 1/4885ABCB11 9/4885 |
| US-10414791-B2 | Methods for preparation of bile acids and derivatives thereof | SLC10A1, NR1H4, SLC10A2 | NR1H4 2/4885GPBAR1 4/4885ABCB11 6/4885 |
| US-20210139528-A1 | CRYSTALLINE FORMS OF OBETICHOLIC ACID | OTC, OSTC, CEL | NR1H4 23/4885GPBAR1 25/4885ABCB11 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.